| Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones |
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission |
globenewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting |
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations |
globenewswire.com |
2025-05-09 21:00:00 |
Czytaj oryginał (ang.) |
| Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress |
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on the neuroprotective effect of ANX007, including consistent benefits of C1q inhibition against inflammation and neuronal damage across diseases. |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on April 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-16 20:05:00 |
Czytaj oryginał (ang.) |
| Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck |
Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting with the FDA in H1 2025. The company has $312 million in cash, enough to fund operations into H2 2026, reducing the need for imminent fundraising. Annexon is also developing ANX007 for Geographic Atrophy, with key milestones including enrollment completion in H2 2025 and topline data in H2 2026. |
seekingalpha.com |
2025-04-15 11:12:10 |
Czytaj oryginał (ang.) |
| Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting |
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS |
globenewswire.com |
2025-04-08 20:05:00 |
Czytaj oryginał (ang.) |
| Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting |
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points |
globenewswire.com |
2025-04-03 22:18:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-17 18:05:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones |
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission Established Groundbreaking Global Registration Path for ANX007 to be Potential First Vision-Preserving Treatment for Dry AMD with GA in Europe and U.S.; Topline Phase 3 ARCHER II Data Expected Second Half 2026 First-in-Kind Oral C1s Inhibitor POC Trial Ongoing with Dosing in Three Patients with Cold Agglutin Disease; Expanded ANX1502 Dataset to Include Up to Seven Patients Expected Mid-2025 Strong Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $312 Million as of December 31, 2024, and Anticipated Runway into Second Half 2026 BRISBANE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2024 financial results. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference |
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:50 a.m. EST. |
globenewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting |
BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on ANX007 in geographic atrophy (GA) at the Macula Society 48th Annual Meeting being held February 12-15 in Charlotte Harbor, Florida. |
globenewswire.com |
2025-02-13 10:30:00 |
Czytaj oryginał (ang.) |
| Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PST. |
globenewswire.com |
2025-01-07 10:00:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-16 18:05:00 |
Czytaj oryginał (ang.) |
| Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) |
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif. |
globenewswire.com |
2024-12-16 09:30:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-15 18:59:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones |
Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 |
globenewswire.com |
2024-11-14 10:00:00 |
Czytaj oryginał (ang.) |
| Annexon Biosciences to Present at the Jefferies London Healthcare Conference |
BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT. |
globenewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting |
Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD). |
globenewswire.com |
2024-10-22 00:00:00 |
Czytaj oryginał (ang.) |
| Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX) |
On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104. |
gurufocus.com |
2024-10-03 05:20:15 |
Czytaj oryginał (ang.) |
| Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS |
Annexon's ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company's pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver. |
seekingalpha.com |
2024-08-17 13:28:11 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-08-16 20:05:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-07-16 20:05:00 |
Czytaj oryginał (ang.) |
| Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting |
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation |
globenewswire.com |
2024-07-11 22:09:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Annexon (ANNX) This Year? |
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year. |
zacks.com |
2024-06-28 14:45:34 |
Czytaj oryginał (ang.) |
| Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now |
After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-06-27 14:55:24 |
Czytaj oryginał (ang.) |
| Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting |
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints |
globenewswire.com |
2024-06-25 21:00:00 |
Czytaj oryginał (ang.) |
| Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 14, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-06-17 20:05:00 |
Czytaj oryginał (ang.) |
| Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? |
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year. |
zacks.com |
2024-06-07 14:41:35 |
Czytaj oryginał (ang.) |
| Annexon Announces Pricing of $125 Million Underwritten Public Offering |
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. |
globenewswire.com |
2024-06-06 03:04:00 |
Czytaj oryginał (ang.) |
| Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals |
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome. |
zacks.com |
2024-06-05 16:00:25 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet |
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-06-05 14:55:22 |
Czytaj oryginał (ang.) |
| Annexon Announces Proposed Public Offering of Common Stock |
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $125 million of shares of its common stock. All of the shares are being offered by Annexon. In addition, Annexon expects to grant the underwriters a 30-day option to purchase up to an additional $18.750 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. |
globenewswire.com |
2024-06-04 21:06:00 |
Czytaj oryginał (ang.) |